Fig. 1: Trial profile. | Nature Medicine

Fig. 1: Trial profile.

From: Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial

Fig. 1: Trial profile.The alternative text for this image may have been generated using AI.

Infant deaths were captured from birth to 14 weeks. A single asterisk indicates primary analysis datasets for baseline demographic characteristics and safety analyses. Dagger indicates primary analysis datasets for immunogenicity analyses. Main reasons for discontinuation among the randomized women were withdrawal by participant (72/2,013 (3.6%)), loss to follow-up (14/2,013 (0.7%)) and new pregnancy during the study (8/2,013 (0.4%)). Double asterisk indicates data from group C (n = 5) were analyzed separately and are not included in this paper.

Back to article page